This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
A massive 5 year–plus effort to find molecularly targeted therapies for patients with recurrent, advanced-stage squamous cell carcinoma of the lungs has demonstrated the feasibility of rapidly screening tumors for rare genomic alterations and assigning drug treatments accordingly. Yet, the Lung Cancer Master Protocol study has yet to identify a broadly effective targeted agent for patients with biomarker-defined subtypes of the disease.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
January 2021
Volume 11, Issue 1
Volume 11, Issue 1
Targeted Drugs Fall Short in Squamous Lung Cancer
Jump to section
Advertisement